Vir Biotechnology has reported that its combination therapy for chronic hepatitis D (CHD) has achieved an 88% rate of viral suppression in recent findings presented in May 2026. The data indicates a significant advancement in the treatment of this viral infection, which has historically been challenging to manage. The results were shared during a presentation, highlighting the potential effectiveness of the therapy in improving patient outcomes. Further details regarding the study's methodology and participant demographics were also included in the presentation.
Related Articles
Don't miss out on breaking stories and in-depth articles.